Welcome to LookChem.com Sign In|Join Free
  • or
Benzamide, N-[2-[(3-cyano-5,7-dimethyl-2-quinolinyl)amino]ethyl]-3-methoxy- (9CI) is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

606101-83-1

Post Buying Request

606101-83-1 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

606101-83-1 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 606101-83-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 6,0,6,1,0 and 1 respectively; the second part has 2 digits, 8 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 606101-83:
(8*6)+(7*0)+(6*6)+(5*1)+(4*0)+(3*1)+(2*8)+(1*3)=111
111 % 10 = 1
So 606101-83-1 is a valid CAS Registry Number.

606101-83-1SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 19, 2017

Revision Date: Aug 19, 2017

1.Identification

1.1 GHS Product identifier

Product name N-[2-[(3-cyano-5,7-dimethylquinolin-2-yl)amino]ethyl]-3-methoxybenzamide

1.2 Other means of identification

Product number -
Other names HMS1705K09

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:606101-83-1 SDS

606101-83-1Downstream Products

606101-83-1Relevant academic research and scientific papers

CYANOQUINOLINE COMPOUNDS HAVING ACTIVITY IN CORRECTING MUTANT-CFTR PROCESSING AND INCREASING ION TRANSPORT AND USES THEREOF

-

, (2013/02/28)

The present disclosure provides pharmaceutical compositions, pharmaceutical preparations and methods for increasing activity of a mutant cystic fibrosis transmembrane conductance regulator protein (mutant-CFTR). The pharmaceutical compositions, pharmaceut

Cyanoquinolines with independent corrector and potentiator activities restore ΔPhe508-cystic fibrosis transmembrane conductance regulator chloride channel function in cystic fibrosis

Phuan, Puay-Wah,Yang, Baoxue,Knapp, John M.,Wood, Alex B.,Lukacs, Gergely L.,Kurth, Mark J.,Verkman, Alan S.

, p. 683 - 693 (2012/06/04)

The ΔPhe508 mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) protein impairs its folding, stability, and chloride channel gating. Although small molecules that separately correct defective ΔPhe508-CFTR folding/cellular processing

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 606101-83-1